Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Change in Receivables came in at -$203.2 million in Q1 2026, down 150407.41% YoY from N/an in Q1 2025, and down 195.82% on a QoQ basis from $212.0 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 16 years of Change in Receivables data on file, last reported at -$203.2 million in Q1 2026.
- Quarterly Change in Receivables fell 150407.41% year-over-year to -$203.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.5 million (up 2583.42% YoY) and the FY2025 annual result came in at $57.0 million, changed N/A from the prior year.
- Change in Receivables fell to -$203.2 million in Q1 2026, from $212.0 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $212.0 million in Q4 2025 to a low of -$203.2 million in Q1 2026.
- A 5-year average of $5.1 million and a median of $1.2 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 8381.84% — and 2026, when it slumped 150407.41%.
- Tracing ARWR's Change in Receivables over 5 years: stood at $38.2 million in 2022, then tumbled by 103.27% to -$1.2 million in 2023, then jumped by 300.64% to $2.5 million in 2024, then jumped by 8381.84% to $212.0 million in 2025, then slumped by 195.82% to -$203.2 million in 2026.
- The last three Change in Receivables figures came in at -$203.2 million (Q1 2026), $212.0 million (Q4 2025), and $47.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.95 Mn |
| Jun 30, 2026 | -6.95 Mn |
| Mar 31, 2026 | -203.19 Mn |
| Mar 31, 2026 | -203.19 Mn |
| Dec 31, 2025 | 212.05 Mn |
| Dec 31, 2025 | 212.05 Mn |
| Sep 30, 2025 | 47.13 Mn |
| Sep 30, 2025 | 47.13 Mn |
| Jun 30, 2025 | 7.48 Mn |
| Jun 30, 2025 | 7.48 Mn |
| Mar 31, 2025 | -135,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Dec 31, 2024 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2023 | -1.25 Mn |
| Sep 30, 2023 | -1.25 Mn |
| Jun 30, 2023 | -68.19 Mn |
| Jun 30, 2023 | -68.19 Mn |
| Mar 31, 2023 | 29.87 Mn |
| Mar 31, 2023 | 29.87 Mn |